Treadwell Therapeutics

Oncology Small Molecules

Also 5 additional trials Clin1 multiple cancers; CFI-402257 Clin1 breast cancer, 2 additional trials Clin1 breast cancer, solid tumors; CFI-402411 Clin1 solid tumors; undisclosed programs RD/Clin0 multiple cancers

Treadwell Therapeutics is developing novel therapeutics to treat highly aggressive cancers. Building upon work uncovered from their scientific co-founders, Treadwell is focused on drug discovery and development to identify promising targets and programs to treat cancer. This involves the combination of RNAi screens, cell surface protein screens, knockout mice technology and their human B-cell mining platform to identify tumor vulnerabilities. Treadwell’s pipeline includes therapeutics for multiple targets as well as various modalities, including small molecules and T cell therapies. Their lead program, TWT-202, is a small molecule that has entered clinical trials for AML patients.